BACKGROUND: Although the bcl-2 proto-oncogene is important in determining tumor cell susceptibility to apoptosis, no data about the clinical importance in gastric cancer are available. METHODS: We analyzed bcl-2 and p53 expression, proliferative activity, and tumor apoptosis in locally advanced gastric carcinomas from 84 patients. RESULTS: Immunohistochemical analysis indicated that 41.7% and 48.8% of the tumors were bcl-2-positive, respectively. The apoptotic fraction was significantly lower in bcl-2-positive than negative tumors. Univariate analysis indicated low apoptotic fraction was one of the poor prognostic factors. Multivariate analysis showed a trend toward improved survival in bcl-2-positive patients. In patients with lymph node metastases more severe than group 2 lymph node, survival was significantly longer in those with bcl-2-positive tumors. CONCLUSIONS: The expression of bcl-2 and the high apoptotic fraction were concluded to be important prognostic factors of survival in patients with advanced gastric cancer.
BACKGROUND: Although the bcl-2 proto-oncogene is important in determining tumor cell susceptibility to apoptosis, no data about the clinical importance in gastric cancer are available. METHODS: We analyzed bcl-2 and p53 expression, proliferative activity, and tumor apoptosis in locally advanced gastric carcinomas from 84 patients. RESULTS: Immunohistochemical analysis indicated that 41.7% and 48.8% of the tumors were bcl-2-positive, respectively. The apoptotic fraction was significantly lower in bcl-2-positive than negative tumors. Univariate analysis indicated low apoptotic fraction was one of the poor prognostic factors. Multivariate analysis showed a trend toward improved survival in bcl-2-positive patients. In patients with lymph node metastases more severe than group 2 lymph node, survival was significantly longer in those with bcl-2-positive tumors. CONCLUSIONS: The expression of bcl-2 and the high apoptotic fraction were concluded to be important prognostic factors of survival in patients with advanced gastric cancer.
Authors: C J van der Woude; J H Kleibeuker; A T G M Tiebosch; M Homan; A Beuving; P L M Jansen; H Moshage Journal: J Clin Pathol Date: 2003-09 Impact factor: 3.411
Authors: Paolo Aurello; Niccolò Petrucciani; Laura Antolino; Diego Giulitti; Francesco D'Angelo; Giovanni Ramacciato Journal: World J Gastroenterol Date: 2017-05-21 Impact factor: 5.742
Authors: Mariusz Gryko; Anna Pryczynicz; Konrad Zareba; Bogusław Kędra; Andrzej Kemona; Katarzyna Guzińska-Ustymowicz Journal: J Immunol Res Date: 2014-02-19 Impact factor: 4.818